Oppenheimer upgraded Alnylam (ALNY) to Outperform from Perform with a $490 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma: Hold Rating Amid Strong Sales and Elevated Costs
- Alnylam’s Q2 2025 Earnings Call Highlights Robust Growth
- Alnylam price target raised to $459 from $385 at Truist
- Alnylam price target raised to $450 from $342 at Scotiabank
- Alnylam price target raised to $424 from $370 at Raymond James